Contemporary Pediatrician, Digital Edition, July 2012

Article

Type 2 Diabetes : Diagnostic, treatment challenges Dyslipidemia : New NHLBI guidelines Adolescent anxiety disorders : Effective therapy, medication options Dermcase : Newborn with persistent rash on foot Puzzler : Vomiting and failure to thrive in breastfeed infant In type 2 diabetes, the ability of insulin protein (left) to interact properly with glucose molecules (right) is compromised.

Related Videos
Perry Roy, MD | Image Credit: Carolina Attention Specialists
Angela Nash, PhD, APRN, CPNP-PC, PMHS | Image credit: UTHealth Houston
Allison Scott, DNP, CPNP-PC, IBCLC
Joanne M. Howard, MSN, MA, RN, CPNP-PC, PMHS & Anne Craig, MSN, RN, CPNP-PC
Juanita Mora, MD
Natasha Hoyte, MPH, CPNP-PC
Lauren Flagg
Venous thromboembolism, Heparin-induced thrombocytopenia, and direct oral anticoagulants | Image credit: Contemporary Pediatrics
Jessica Peck, DNP, APRN, CPNP-PC, CNE, CNL, FAANP, FAAN
Sally Humphrey, DNP, APRN, CPNP-PC | Image Credit: Contemporary Pediatrics
Related Content
BLA resubmitted for lebrikizumab to treat AD patients 12 years and up | Image Credit: © Araki Illustrations - © Araki Illustrations - stock.adobe.com.

BLA resubmitted for lebrikizumab to treat AD patients 12 years and up

April 30th 2024
Article

The resubmission was announced in a first quarter, 2024 earnings news release from Lilly, which expects "regulatory action in the second half of 2024."

Site Logo

Food Insecurity and the Dangers of Infant Formula Dilution

January 30th 2023
Podcast
Perry Roy, MD

A deep dive into Qbtech's diagnostic ADHD test

April 30th 2024
Article

A discussion based on an FDA-cleared objective ADHD diagnostic test developed by Qbtech.

Demystifying Infant Formula

Demystifying Infant Formula

October 11th 2022
Podcast
FDA accepts sNDA for tapinarof cream, 1% to treat AD in children 2 years and up | Image Credit: © Araki Illustrations - © Araki Illustrations - stock.adobe.com.

FDA accepts sNDA for tapinarof cream, 1% to treat AD in children 2 years and up

April 29th 2024
Article

A decision from the federal agency is expected in the fourth quarter of 2024.

FDA approves diazepam for seizure clusters in patients 2 to 5 years | Image Credit: © Calin - © Calin - stock.adobe.com.

FDA approves diazepam for seizure clusters in patients 2 to 5 years

April 29th 2024
Article

With the approval comes the immediate availability of 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg doses for patients between 2 to 5 years of age.

© 2024 MJH Life Sciences

All rights reserved.